Get started
Work

Phase 2 study to evaluate safety and efficacy of MEDI4736 (durvalumab [DUR]) in glioblastoma (GBM) patients: An update.

Year: 2017
Type: conference-abstract
DOI: 10.1200/jco.2017.35.15_suppl.2042
Authors: David A. Reardon, Thomas Joseph Kaley, Jorg Dietrich, Jennifer Leigh Clarke, Gavin P Dunn, Michael Lim, Timothy Francis Cloughesy, Hui Kong Gan, Andrew J. Park, Paul Schwarzenberger, Toni Ricciardi, Mary J. Macri, Aileen Ryan, Ralph Rudolph Venhaus
Institutions: Harvard University, Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Massachusetts General Hospital, University of California, San Francisco, Washington University in St. Louis, Johns Hopkins University, Johns Hopkins Hospital, University of California, Los Angeles, Austin Health, Olivia Newton-John Cancer Research Institute, Ludwig Cancer Research
Language: English
Subfield: Genetics
Field: Medicine
Open Access status: closed
OpenAlex ID: W2643663241
Cites:
Cited by: 49
Related to: 10